Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia

Xuechan Lyu, Jiang Du, Guilai Zhan, Yujie Wu, Hang Su, Youwei Zhu, Fredrik Jarskog, Min Zhao, Xiaoduo Fan, Xuechan Lyu, Jiang Du, Guilai Zhan, Yujie Wu, Hang Su, Youwei Zhu, Fredrik Jarskog, Min Zhao, Xiaoduo Fan

Abstract

Objective: The rates of obesity and cigarette smoking are much higher in patients with schizophrenia compared to the general population. This study was to examine whether naltrexone and bupropion combination treatment can help weight loss and smoking cessation in patients with schizophrenia. Methods: Obese male schizophrenia patients with current cigarette smoking were randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day) combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study, and 21 patients completed the study (11 in the treatment group, and 10 in the placebo group). Body weight, body mass index (BMI), fasting lipids, smoking urge, expired carbon monoxide (CO) level and cigarettes smoked per week were measured at baseline and week 24. Results: There was no significant difference between two groups in changes in weight, BMI, fasting lipids, or cigarette smoking measures (p's > 0.05) Conclusion: Naltrexone and bupropion combination treatment didn't show weight loss or smoking cessation effect in patients with schizophrenia in this pilot study.Implications for future studies were discussed. ClinicalTrials.gov identifier: NCT02736474.

Keywords: Schizophrenia; bupropion; naltrexone; smoking cessation; weight loss.

References

    1. Allison D. B., Casey D. E. (2001). Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 62(Suppl. 7.), 22–31.
    1. Anderson J. W., Greenway F. L., Fujioka K., Gadde K. M., McKenney J., O'Neil P. M. (2002). Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes. Res. 10, 633–641. 10.1038/oby.2002.86
    1. Berridge K. C., Ho C. Y., Richard J. M., Difeliceantonio A. G. (2010). The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res. 1350, 43–64. 10.1016/j.brainres.2010.04.003
    1. Billes S. K., Sinnayah P., Cowley M. A. (2014). Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol. Res. 84, 1–11. 10.1016/j.phrs.2014.04.004
    1. Brown S., Inskip H., Barraclough B. (2000). Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 177, 212–217. 10.1192/bjp.177.3.212
    1. Cather C., Pachas G. N., Cieslak K. M., Evins A. E. (2017). Achieving Smoking Cessation in Individuals with Schizophrenia: special Considerations. CNS Drugs 31, 471–481. 10.1007/s40263-017-0438-8
    1. Culbertson C. S., Bramen J., Cohen M. S., London E. D., Olmstead R. E., Gan J. J., et al. . (2011). Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. Arch. Gen. Psychiatry 68, 505–515. 10.1001/archgenpsychiatry.2010.193
    1. de Leon J., Diaz F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 76, 135–157. 10.1016/j.schres.2005.02.010
    1. Farley A. C., Hajek P., Lycett D., Aveyard P. (2009). Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 1:CD006219. 10.1002/14651858.CD006219.pub3
    1. Greenway F. L., Fujioka K., Plodkowski R. A., Mudaliar S., Guttadauria M., Erickson J., et al. . (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376, 595–605. 10.1016/S0140-6736(10)60888-4
    1. Greenway F. L., Whitehouse M. J., Guttadauria M., Anderson J. W., Atkinson R. L., Fujioka K., et al. . (2009). Rational design of a combination medication for the treatment of obesity. Obesity 17, 30–39. 10.1038/oby.2008.461
    1. Guo X., Zhang Z., Wei Q., Lv H., Wu R., Zhao J. (2013). The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry 13:109. 10.1186/1471-244X-13-109
    1. Hall S. M., McGee R., Tunstall C., Duffy J., Benowitz N. (1989). Changes in food intake and activity after quitting smoking. J. Consul. Clin. Psychol. 57, 81–86. 10.1037/0022-006X.57.1.81
    1. Hollander P., Gupta A. K., Plodkowski R., Greenway F., Bays H., Burns C., et al. . (2013). Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36, 4022–4029. 10.2337/dc13-0234
    1. Hou Y. Z., Xiang Y. T., Yan F., Ungvari G. S., Dickerson F., Chiu H. F., et al. . (2011). Cigarette smoking in community-dwelling patients with schizophrenia in China. J. Psychiatr. Res. 45, 1551–1556. 10.1016/j.jpsychires.2011.07.011
    1. Hruby A., Manson J. E., Qi L., Malik V. S., Rimm E. B., Sun Q., et al. . (2016). Determinants and consequences of obesity. Am. J. Public Health 106, 1656–1662. 10.2105/AJPH.2016.303326
    1. King A. C., Cao D., O'Malley S. S., Kranzler H. R., Cai X., dewit H., et al. . (2012). Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J. Clin. Psychopharmacol. 32, 630–636. 10.1097/JCP.0b013e3182676956
    1. King A. C., Cao D., Zhang L., O'Malley S. S. (2013). Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol. Psychiatry. 73, 924–930. 10.1016/j.biopsych.2012.09.025
    1. Lerman C., Berrettini W., Pinto A., Patterson F., Crystal-mansour S., Wileyto E. P., et al. . (2004). Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology 174, 571–577. 10.1007/s00213-004-1823-9
    1. Mansvelder H. D., Mertz M., Role L. W. (2009). Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. Semin. Cell Dev. Biol. 20, 432–440. 10.1016/j.semcdb.2009.01.007
    1. Marder S. R., Essock S. M., Miller A. L., Buchanan R. W., Casey D. E., Davis J. M., et al. . (2004). Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 161, 1334–1349. 10.1176/appi.ajp.161.8.1334
    1. Morisano D., Bacher I., Audrain-McGovern J., George T. P. (2009). Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Can. J. Psychiatry 54, 356–367. 10.1177/070674370905400603
    1. Osby U., Correia N., Brandt L., Ekbom A., Sparén P. (2000). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 45, 21–28. 10.1016/S0920-9964(99)00191-7
    1. Tsoi D. T., Porwal M., Webster A. C. (2010). Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 196, 346–353. 10.1192/bjp.bp.109.066019
    1. Wadden T. A., Foreyt J. P., Foster G. D., Hill J. O., Klein S., O'Neil P. M., et al. . (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 19, 110–120. 10.1038/oby.2010.147
    1. Wilcox C. S., Oskooilar N., Erickson J. S., Billes S. K., Katz B. B., Tollefson G., et al. . (2010). An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict. Behav. 35, 229–234. 10.1016/j.addbeh.2009.10.017
    1. Wing V. C., Wass C. E., Soh D. W., George T. P. (2012). A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann. N. Y. Acad. Sci. 1248, 89–106. 10.1111/j.1749-6632.2011.06261.x
    1. Winterer G. (2010). Why do patients with schizophrenia smoke? Curr. Opin. Psychiatry 23, 112–119. 10.1097/YCO.0b013e3283366643
    1. Wu Y. (2006). Overweight and obesity in China. BMJ 333, 362–363. 10.1136/bmj.333.7564.362
    1. Yang M., Bhowmik D., Wang X., Abughosh S. (2013). Does combination pharmacological intervention for smoking cessation prevent post-cessation weight gain? a systemic review. Addict. Behav. 38, 1865–1875. 10.1016/j.addbeh.2012.11.007
    1. Zhang X. Y., Liang J. C., Chen D. C., Xiu M. H., He J., Cheng W., et al. . (2012). Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes. PLoS ONE 7:e30937. 10.1371/journal.pone.0030937

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere